The P2X7R-NLRP3 inflammasome axis in Alzheimer’s disease and therapeutic potential of synthetic and plant-derived natural compounds: A review

Abstract

Alzheimer’s disease is a prevalent neurodegenerative disease that is characterized by synaptic dysfunction followed by neuronal loss. The core pathological mechanisms of Alzheimer’s disease include the extracellular deposition of amyloid beta (Aβ) plaques and intracellular neurofibrillary tangle deposits inside the brain. These pathological hallmarks initiate the activation of neuro-immunological pathways that lead to neuronal loss. Aβ aggregation and neurofibrillary tangles function as danger signals and cause the release of extracellular adenosine‑5′‑triphosphate (ATP) from stressed or damaged neurons. The released ATP further amplifies the neuroinflammatory response by activating the P2X7 receptor (P2X7R) on microglial cells, which in turn facilitates NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome complex formation and activation. The latter event leads to caspase-1 activation-mediated release of cytokines, including interleukin-1β and interleukin-18, followed by pyroptotic cell death. Consequently, this neuroinflammatory cascade results in cognitive impairment. Despite intensive research efforts, direct therapeutic targeting of the P2X7R has yielded limited clinical success, partly due to receptor compensatory mechanisms and genetic polymorphisms that affect treatment responsiveness. In this context, emerging evidence highlights the potential of targeting the downstream NLRP3 inflammasome via natural bioactive compounds or synthetic molecules as a more promising therapeutic strategy for modulating the neuroinflammatory pathways underlying Alzheimer’s pathogenesis. Collectively, this review summarizes the progressive molecular events linking Aβ and tau pathology to neuroinflammation via the P2X7R-NLRP3 inflammasome axis, while underscoring the therapeutic potential of plant-derived bioactive compounds as well as synthetic molecules in mitigating the progression of Alzheimer’s disease.

Keywords

Alzheimer’s disease / Neuroinflammation / Neurodegenertaion / Neuroprotection / NLRP3 / Purinergic / P2X7 receptor / Interleukin

References

[1] Alzheimer's Association. 2026 Alzheimer's disease facts and figures. Alzheimers Dement 2026; 22(3): 321-387. doi: 10.1002/alz.71345.

[2] Bagaria J, Bagyinszky E, An SSA. Genetics, functions, and clinical impact of presenilin-1 (PSEN1) gene. Int J Mol Sci 2022; 23(18): 10970. doi: 10.3390/ijms231810970.

[3] Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(10): a006296. doi: 10.1101/cshperspect.a006296.

[4] Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol 2018; 217(2): 459-472. doi: 10.1083/jcb.201709069.

[5] Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016; 352(6286): 712-716. doi: 10.1126/science.aad8373.

[6] Espay AJ, Kepp KP, Herrup K. Lecanemab and donanemab as therapies for Alzheimer's disease: An illustrated perspective on the data. eNeuro 2024; 11(7). doi: 10.1523/ENEURO.0319-23.2024.

[7] Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med 2017; 23(9): 1018-1027. doi: 10.1038/nm.4397.

[8] Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007; 87(2): 659-797. doi: 10.1152/physrev.00043.2006.

[9] Falzoni S, Donvito G, Di Virgilio F. Detecting adenosine triphosphate in the pericellular space. Interface Focus 2013; 3(3). doi: 10.1098/rsfs.2012.0101.

[10] Trautmann A. Extracellular ATP in the immune system: More than just a "danger signal." Sci Signal 2009; 2(56). doi: 10.1126/scisignal.256pe6.

[11] Zheng H, Liu Q, Zhou S, Luo H, Zhang W. Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases. Front Immunol 2024; 15. doi: 10.3389/fimmu.2024.1345625.

[12] Kierdorf K, Prinz M. Microglia in steady state. J Clin Invest 2017; 127(9): 3201-3209. doi: 10.1172/JCI90602.

[13] Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013; 493(7434): 674-678. doi: 10.1038/nature11729.

[14] Miras-Portugal MT, Sebastián-Serrano Á, de Diego García L, Díaz-Hernández M. Neuronal P2X7 receptor: Involvement in neuronal physiology and pathology. J Neurosci 2017; 37(30): 7063-7072. doi: 10.1523/JNEUROSCI.3104-16.2017.

[15] Martinez-Cuesta MÁ, Blanch-Ruiz MA, Ortega-Luna R, Sánchez-López A, Álvarez Á. Structural and functional basis for understanding the biological significance of P2X7 receptor. Int J Mol Sci 2020; 21(22). doi: 10.3390/ijms21228454.

[16] Lalo U, Pankratov Y. ATP-mediated signalling in the central synapses. Neuropharmacology 2023; 229. doi: 10.1016/j.neuropharm.2023.109477.

[17] Kaur S, Giri VK, Aran KR. Purinergic P2X7 receptor signaling in anxiety: Roles of stress-related neuroinflammatory mechanisms and therapeutic horizons. Purinergic Signal 2026; 22(1): 21. doi: 10.1007/s11302-026-10134-w.

[18] Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J Neuroinflammation 2014; 11. doi: 10.1186/1742-2094-11-98.

[19] Skaper SD, Debetto P, Giusti P. The P2X7 purinergic receptor: From physiology to neurological disorders. FASEB J 2010; 24(2): 337-345. doi: 10.1096/fj.09-138883.

[20] Yue N, Huang H, Zhu X, Han Q, Wang Y, Li B, et al. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors. J Neuroinflammation 2017; 14(1): 102. doi: 10.1186/s12974-017-0865-y.

[21] Sperlagh B, Illes P. P2X7 receptor: An emerging target in central nervous system diseases. Trends Pharmacol Sci 2014; 35(10): 537-547. doi: 10.1016/j.tips.2014.08.002.

[22] Grygorowicz T, Strużyńska L. Early P2X7 receptor intervention in the course of CNS pathology as a potential therapeutic strategy. Neurochem Int 2018; 119: 1-11. doi: 10.1016/j.neuint.2017.11.001.

[23] Ni J, Wang P, Zhang J, Chen W, Gu L. Silencing of the P2X(7) receptor enhances amyloid-β phagocytosis by microglia. Biochem Biophys Res Commun 2013; 434(2): 363-369. doi: 10.1016/j.bbrc.2013.03.079.

[24] Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature 2019; 575(7784): 669-673. doi: 10.1038/s41586-019-1769-z.

[25] Lin L, Li Z, Su F, Huang H, Huang S, Chen WN, et al. An autonomous siRNA delivery system targeting NLRP3: Implications in Parkinson's disease. BMC Med 2026; 24(1): 166. doi: 10.1186/s12916-026-04688-0.

[26] Tastan B, Cotuk A, Arioz BI, Karacicek B, Ture B, Tastan N, et al. Long non-coding RNA NEAT1 modulates microglial NLRP3 inflammasome activation. J Neuroimmunol 2025; 409. doi: 10.1016/j.jneuroim.2025.578770.

[27] Territo PR, Zarrinmayeh H. P2X7 Receptors in neurodegeneration: Potential therapeutic applications from basic to clinical approaches. Front Cell Neurosci 2021; 15. doi: 10.3389/fncel.2021.617036.

[28] Lenertz LY, Gavala ML, Hill LM, Bertics PJ. Cell signaling via the P2X(7) nucleotide receptor: Linkage to ROS production, gene transcription, and receptor trafficking. Purinergic Signal 2009; 5(2): 175-187. doi: 10.1007/s11302-009-9133-7.

[29] Angelova PR, Abramov AY. Role of mitochondrial ROS in the brain: From physiology to neurodegeneration. FEBS Lett 2018; 592(5): 692-702. doi: 10.1002/1873-3468.12964.

[30] Sayas CL, Ávila J. GSK-3 and tau: A key duet in Alzheimer's disease. Cells 2021; 10(4): 721. doi: 10.3390/cells10040721.

[31] Curro D, Navarra P, Samengo I, Martire M. P2X7 receptors exert a permissive effect on the activation of presynaptic AMPA receptors in rat trigeminal caudal nucleus glutamatergic nerve terminals. J Headache Pain 2020; 21(1): 83. doi: 10.1186/s10194-020-01153-y.

[32] Andrejew R, Oliveira-Giacomelli Á, Ribeiro DE, Glaser T, Arnaud-Sampaio VF, Lameu C, et al. The P2X7 receptor: Central hub of brain diseases. Front Mol Neurosci 2020; 13. doi: 10.3389/fnmol.2020.00124.

[33] Hanisch UK, Kettenmann H. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10(11): 1387-1394. doi: 10.1038/nn1997.

[34] Town T, Nikolic V, Tan J. The microglial "activation" continuum: From innate to adaptive responses. J Neuroinflammation 2005; 2. doi: 10.1186/1742-2094-2-24.

[35] Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 2016; 53(2): 1181-1194. doi: 10.1007/s12035-014-9070-5.

[36] Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011; 333(6048): 1456-1458. doi: 10.1126/science.1202529.

[37] Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, Boche D, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol 2025; 25(5): 321-352. doi: 10.1038/s41577-024-01104-7.

[38] Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007; 28(3): 138-145. doi: 10.1016/j.it.2007.01.005.

[39] Serrano-Pozo A, Mielke ML, Gómez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol 2011; 179(3): 1373-1384. doi: 10.1016/j.ajpath.2011.05.047.

[40] Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017; 541(7638): 481-487. doi: 10.1038/nature21029.

[41] Verkhratsky A, Parpura V, Rodriguez-Arellano JJ, Zorec R. Astroglia in Alzheimer's disease. In: Verkhratsky A, Ho MS, Zorec R, Parpura V (eds.) Neuroglia in neurodegenerative diseases. Singapore: Springer; 2019, p. 273-324.

[42] Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A, et al. Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. eLife 2018; 7. doi: 10.7554/eLife.36217.

[43] Domercq M, Pérez-Samartín A, Aparicio D, Alberdi E, Pampliega O, Matute C. P2X7 receptors mediate ischemic damage to oligodendrocytes. Glia 2010; 58(6): 730-740. doi: 10.1002/glia.20958.

[44] Vanshita, Bajpai M. Phytochemistry and pharmacology of Dalbergia sissoo Roxb. ex DC: A review. J Pharm Pharmacol 2023; 75(4): 482-501. doi: 10.1093/jpp/rgac106.

[45] Gnanaraja R, Prakash V, Peter S, Mahendraverman M. Qualitative and quantitative phytochemicals analysis of selected Fabaceae medicinal plants from Allahabad region. Pharma Innovation 2014; 3(7): 53-56.

[46] Sau S, Handral M. Evaluation of memory enhancing activity of leaf extract of Dalbergia sissoo in mice. Int J Pharm Sci Drug Res 2015; 7(3): 263-269. doi: 10.25004/IJPSDR.2015.070307.

[47] Swaroop TVSS, Banerjee S, Handral M. Neuroprotective evaluation of leaf extract of Dalbergia sissoo in 3-nitropropionic acid induced neurotoxicity in rats. Int J Pharm Sci Drug Res 2014; 6(1): 41-47. doi: 10.25004/IJPSDR.2014.060107.

[48] Raheja S, Girdhar A, Kamboj A, Lather V, Pandita D. Protective effect of Dalbergia sissoo extract against amyloid-β (1-42)-induced memory impairment, oxidative stress, and neuroinflammation in rats. Turk J Pharm Sci 2021; 18(1): 104-110. doi: 10.4274/tjps.galenos.2020.04379.

[49] Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005; 49(5): 472-481. doi: 10.1002/mnfr.200500010.

[50] Ramalingam P, Ko YT. Validated LC-MS/MS method for simultaneous quantification of resveratrol levels in mouse plasma and brain and its application to pharmacokinetic and brain distribution studies. J Pharm Biomed Anal 2016; 119: 71-75. doi: 10.1016/j.jpba.2015.11.026.

[51] Feng J, Ji K, Pan Y, Huang P, He T, Xing Y. Resveratrol ameliorates retinal ischemia-reperfusion injury by modulating the NLRP3 inflammasome and Keap1/Nrf2/HO-1 signaling pathway. Mol Neurobiol 2024; 61(10): 8454-8466. doi: 10.1007/s12035-024-04105-8.

[52] Bissacotti BF, da Silveira MV, Assmann CE, Copetti PM, Santos AFD, Fagan SB, et al. Resveratrol alleviates inflammatory response through P2X7/NLRP3 signaling pathway: In silico and in vitro evidence from activated microglia. Pharmaceuticals (Basel) 2025; 18(7). doi: 10.3390/ph18070950.

[53] Wang C, Chen L, Wen R, Peng L, Chen C, Zhuo R, et al. Pterostilbene mitigates scopolamine-induced cognitive impairment by modulating cholinergic pathway and reducing neuroinflammation. Phytomedicine 2026; 150. doi: 10.1016/j.phymed.2025.157630.

[54] Li Q, Chen L, Liu X, Li X, Cao Y, Bai Y et al. Pterostilbene inhibits amyloid-β-induced neuroinflammation in a microglia cell line by inactivating the NLRP3/caspase-1 inflammasome pathway. J Cell Biochem 2018; 119(8): 7053-7062. doi: 10.1002/jcb.27023.

[55] Xing J, Chen X, Zhong D. Absorption and enterohepatic circulation of baicalin in rats. Life Sci 2005; 78(2): 140-146. doi: 10.1016/j.lfs.2005.04.072.

[56] Yang R, Wang R, Xu A, Zhang J, Ma J. Mitigating neurodegenerative diseases: The protective influence of baicalin and baicalein through neuroinflammation regulation. Front Pharmacol 2024; 15. doi: 10.3389/fphar.2024.1425731.

[57] Huang J, Zhang X, Yang X, Yu Q, Ye F, Chen S, et al. Baicalin exerts neuroprotective actions by regulating the Nrf2-NLRP3 axis in toxin-induced models of Parkinson's disease. Chem Biol Interact 2024; 387. doi: 10.1016/j.cbi.2023.110820.

[58] Jin X, Liu MY, Zhang DF, Zhong X, Du K, Qian P, et al. Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway. CNS Neurosci Ther 2019; 25(5): 575-590. doi: 10.1111/cns.13086.

[59] Ling HP, Ding PF, Zhang JT, Yue TT, Zhang QR, Hang CH. Baicalin attenuates ferroptosis after subarachnoid hemorrhage via the PI3K/AKT/GPX4 and NLRP3 axis. Curr Neuropharmacol 2026. doi: 10.2174/011570159X410095251105164024.

[60] Sharan L, Pal A, Babu SS, Jain R, Banerjee S, Kumar A. Parthenolide attenuates neuroinflammation by targeting NLRP3 inflammasome & mitochondrial dysfunction in experimental diabetic neuropathy. Neuropharmacology 2026; 283. doi: 10.1016/j.neuropharm.2025.110729.

[61] Noureldeen ME, Shahin NN, Amin HAA, El-Sawalhi MM, Ghaiad HR. Parthenolide ameliorates 3 nitropropionic acid-induced Huntington's disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting. Mol Med 2024; 30(1): 158. doi: 10.1186/s10020-024-00917-5.

[62] Fan M, Wang C, Zhao X, Jiang Y, Wang C. Parthenolide alleviates microglia-mediated neuroinflammation via MAPK/TRIM31/NLRP3 signaling to ameliorate cognitive disorder. Int Immunopharmacol 2023; 120. doi: 10.1016/j.intimp.2023.110287.

[63] Ding W, Cai C, Zhu X, Wang J, Jiang Q. Parthenolide ameliorates neurological deficits and neuroinflammation in mice with traumatic brain injury by suppressing STAT3/NF-κB and inflammasome activation. Int Immunopharmacol 2022; 108. doi: 10.1016/j.intimp.2022.108913.

[64] Liu L, Feng L, Gao J, Hu J, Li A, Zhu Y, et al. Parthenolide targets NLRP3 to treat inflammasome-related diseases. Int Immunopharmacol 2023; 119. doi: 10.1016/j.intimp.2023.110229.

[65] Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004; 208(2): 143-153. doi: 10.1016/j.canlet.2003.11.028.

[66] Zhang X, Zhang Y, Li R, Zhu L, Fu B, Yan T. Salidroside ameliorates Parkinson's disease by inhibiting NLRP3-dependent pyroptosis. Aging (Albany NY) 2020; 12(10): 9405-9426. doi: 10.18632/aging.103215.

[67] Cai Y, Chai Y, Fu Y, Wang Y, Zhang Y, Zhang X, et al. Salidroside ameliorates Alzheimer's disease by targeting NLRP3 inflammasome-mediated pyroptosis. Front Aging Neurosci 2022; 13. doi: 10.3389/fnagi.2021.809433.

[68] Ao W, Gao W, Li T. Research progress on the mechanism of antidepressant effect of salidroside. Int Immunopharmacol 2025; 162. doi: 10.1016/j.intimp.2025.115205.

[69] Wu Q, Shan X, Li X, Guan J, Song F, Zhou X, et al. Salidroside ameliorates neuroinflammation in autistic rats by inhibiting NLRP3/Caspase-1/GSDMD signal pathway. Brain Res Bull 2025; 220. doi: 10.1016/j.brainresbull.2024.111132.

[70] You L, Zhang D, Geng H, Sun F, Lei M. Salidroside protects endothelial cells against LPS-induced inflammatory injury by inhibiting NLRP3 and enhancing autophagy. BMC Complement Med Ther 2021; 21(1): 146. doi: 10.1186/s12906-021-03307-0.

[71] Cai Y, Huang G, Ren M, Chai Y, Huang X, Yan T. Synthesizing network pharmacology, bioinformatics, and in vitro experimental verification to screen candidate targets of Salidroside for mitigating Alzheimer's disease. Naunyn Schmiedebergs Arch Pharmacol 2025; 398(4): 4539-4558. doi: 10.1007/s00210-024-03555-0.

[72] Fan F, Yang L, Li R, Zou X, Li N, Meng X, et al. Salidroside as a potential neuroprotective agent for ischemic stroke: A review of sources, pharmacokinetics, mechanism and safety. Biomed Pharmacother 2020; 129. doi: 10.1016/j.biopha.2020.110458.

[73] Zhang Y, Li L, Lin L, Liu J, Zhang Z, Xu D, et al. Pharmacokinetics, tissue distribution, and excretion of salidroside in rats. Planta Med 2013; 79(15): 1429-1433. doi: 10.1055/s-0033-1350807.

[74] Zhang Y, Zhao Y, Zhang J, Gao Y, Li S, Chang C, et al. Ginkgolide B inhibits NLRP3 inflammasome activation and promotes microglial M2 polarization in Aβ_1-42-induced microglia cells . Neurosci Lett 2021; 764. doi: 10.1016/j.neulet.2021.136206.

[75] Du Y, Luo M, Du Y, Xu M, Yao Q, Wang K, et al. Liquiritigenin decreases Aβ levels and ameliorates cognitive decline by regulating microglia M1/M2 transformation in AD mice. Neurotox Res 2021; 39(2): 349-358. doi: 10.1007/s12640-020-00284-z.

[76] Honda H, Nagai Y, Matsunaga T, Okamoto N, Watanabe Y, Tsuneyama K, et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J Leukoc Biol 2014; 96(6): 1087-1100. doi: 10.1189/jlb.3A0114-005RR.

[77] Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21(3): 248-255. doi: 10.1038/nm.3806.

[78] Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med 2018; 10(465). doi: 10.1126/scitranslmed.aah4066.

[79] Perera AP, Fernando R, Shinde T, Gundamaraju R, Southam B, Sohal SS, et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep 2018; 8: 8618. doi: 10.1038/s41598-018-26775-w.

[80] Li H, Guan Y, Liang B, Ding P, Hou X, Wei W, et al. Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome. Eur J Pharmacol 2022; 928. doi: 10.1016/j.ejphar.2022.175091.

[81] He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun 2018; 9(1): 2550. doi: 10.1038/s41467-018-04947-6.

[82] Zhang P, Li Z, Liang M, Yuan J, Zhou J, Zhang J, et al. JC124 confers multimodal neuroprotection in epilepsy by suppressing NLRP3 inflammasome activation: Evidence from animal and human neuronal models. Cell Commun Signal 2025; 23(1): 327. doi: 10.1186/s12964-025-02239-3.

[83] Kuwar R, Rolfe A, Di L, Blevins H, Xu Y, Sun X, et al. A novel inhibitor targeting NLRP3 inflammasome reduces neuropathology and improves cognitive function in Alzheimer's disease transgenic mice. J Alzheimers Dis 2021; 82(4): 1769-1783. doi: 10.3233/JAD-210400.

[84] Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A 2018; 115(7): E1530-E1539. doi: 10.1073/pnas.1716095115.

[85] Sanchez-Fernandez A, Skouras DB, Dinarello CA, López-Vales R. OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis. Front Immunol 2019; 10. doi: 10.3389/fimmu.2019.02578.

[86] Amo-Aparicio J, Daly J, Højen JF, Dinarello CA. Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease. J Neuroinflammation 2023; 20(1): 147. doi: 10.1186/s12974-023-02830-w.

[87] Luque M, Matic M, Heras-Garvin A, Amo-Aparicio J, Luk KC, Haindl MT, et al. Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism. J Neuroinflammation 2026; 23(1): 76. doi: 10.1186/s12974-026-03716-3.

[88] Gatlik E, Mehes B, Voltz E, Sommer U, Tritto E, Lestini G, et al. First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor. Clin Transl Sci 2024; 17(5). doi: 10.1111/cts.13789.

[89] Thornton P, Reader V, Digby Z, Smolak P, Lindsay N, Harrison D, et al. Reversal of high fat diet-induced obesity, systemic inflammation, and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796. J Pharmacol Exp Ther 2024; 388(3): 813-826. doi: 10.1124/jpet.123.002013.

[90] Doedens JR, Smolak P, Nguyen M, Wescott H, Diamond C, Schooley K, et al. Pharmacological analysis of NLRP3 inflammasome inhibitor sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan 2-yl]methyl})sulfamoyl]azanide in cellular and mouse models of inflammation provides a translational framework. ACS Pharmacol Transl Sci 2024; 7(5): 1438-1456. doi: 10.1021/acsptsci.4c00061.

[91] Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med 2017; 214(11): 3219-3238. doi: 10.1084/jem.20171419.

[92] Ambrus-Aikelin G, Takeda K, Joetham A, Lazic M, Povero D, Santini AM, et al. JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders. Sci Rep 2023; 13(1): 13524. doi: 10.1038/s41598-023-39805-z.

[93] Biby S, Mondal P, Xu Y, Gomm A, Kaur B, Namme JN, et al. Functional characterization of an arylsulfonamide-based small-molecule inhibitor of the NLRP3 inflammasome. ACS Chem Neurosci 2024; 15(20): 3721-3733. doi: 10.1021/acschemneuro.4c00512.

[94] Sharma M, Mohapatra J, Patel H, Kale A, Kamiya A, Limje D, et al. Usnoflast: A cutting-edge NLRP3 inhibitor attenuates colonic inflammation across diverse immunopathology. Eur J Pharmacol 2025; 1006. doi: 10.1016/j.ejphar.2025.178117.

[95] Parmar DV, Kansagra KA, Momin T, Patel HB, Jansari GA, Bhavsar J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral NLRP3 inflammasome inhibitor ZYIL1: First-in-human phase 1 studies (Single ascending dose and multiple ascending dose). Clin Pharmacol Drug Dev 2023; 12(2): 202-211. doi: 10.1002/cpdd.1162.

[96] Chatterjee A, Mohapatra J, Sharma M, Jha A, Patro R, Das D, et al. A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson's disease. Brain Res 2024; 1842. doi: 10.1016/j.brainres.2024.149129.

[97] Yeole A, Khanna L, Doshi M, Sharma A, Uttarwar P, Doshi S, et al. A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2025; 26(7-8): 794-801. doi: 10.1080/21678421.2025.2515900.

[98] Yuan Z, Yu D, Gou T, Tang G, Guo C, Shi J. Research progress of NLRP3 inflammasome and its inhibitors with aging diseases. Eur J Pharmacol 2023; 957. doi: 10.1016/j.ejphar.2023.175931.

[99] Oronsky B, Takahashi L, Gordon R, Cabrales P, Caroen S, Reid T. RRx-001: A chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist. Front Oncol 2023; 13. doi: 10.3389/fonc.2023.1204143.

[100] Fang J, She J, Lin F, Wu JC, Han R, Sheng R, et al. RRx-001 Exerts neuroprotection against LPS-induced microglia activation and neuroinflammation through disturbing the TLR4 pathway. Front Pharmacol 2022; 13. doi: 10.3389/fphar.2022.889383.

[101] Shu H, Huang X, Su Z, Liang F, Ding L, Luo K, et al. RRx-001 ameliorates astrocyte pyroptosis by regulating LCN2-NLRP3 inflammasome activation in an MPTP-induced parkinson's disease mouse model. Cell Mol Life Sci 2026; 83(1): 60. doi: 10.1007/s00018-025-06003-1.

[102] Reid T, Oronsky B, Caroen S, Cabrales P. The direct NLRP3 inhibitor and Phase 3 small molecule anticancer agent, RRx-001, protects aged triple transgenic Alzheimer’s disease model mice from CNS degeneration and cognitive decline. Alzheimers Dement 2022; 18(Suppl. 10). doi: 10.1002/alz.061516.

[103] Klughammer B, Piali L, Nica A, Nagel S, Bailey L, Jochum C, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med 2023; 13(11). doi: 10.1002/ctm2.1471.

[104] ClinicalTrials.gov. A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selnoflast in participants with idiopathic early Parkinson's disease. NCT05924243. [Online] Available at: https://clinicaltrials.gov/study/NCT05924243 [Accessed on 27 July, 2026].

[105] Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, et al. Anti-inflammatory compounds parthenolide and Bay 11 7082 are direct inhibitors of the inflammasome. J Biol Chem 2010; 285(13): 9792-9802. doi: 10.1074/jbc.M109.082305.

[106] Lang Y, Chu F, Liu L, Zheng C, Li C, Shen D, et al. Potential role of BAY11-7082, a NF-κB blocker inhibiting experimental autoimmune encephalomyelitis in C57BL/6J mice via declining NLRP3 inflammasomes. Clin Exp Immunol 2022; 207(3): 378-386. doi: 10.1093/cei/uxab022.

[107] Chen X, Wang Y, Yao N, Lin Z. Immunoproteasome modulates NLRP3 inflammasome-mediated neuroinflammation under cerebral ischaemia and reperfusion conditions. J Cell Mol Med 2022; 26(2): 462-474. doi: 10.1111/jcmm.17104.

[108] Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002; 71(4): 286-296. doi: 10.1067/mcp.2002.122476.

[109] Lahmann C, Kramer HB, Ashcroft FM. Systemic administration of glibenclamide fails to achieve therapeutic levels in the brain and cerebrospinal fluid of rodents. PLoS One 2015; 10(7). doi: 10.1371/journal.pone.0134476.

[110] Xu F, Shen G, Su Z, He Z, Yuan L. Glibenclamide ameliorates the disrupted blood-brain barrier in experimental intracerebral hemorrhage by inhibiting the activation of NLRP3 inflammasome. Brain Behav 2019; 9(4). doi: 10.1002/brb3.1254.

[111] Esmaeili MH, Enayati M, Abkenar FK, Ebrahimian F, Salari AA. Glibenclamide mitigates cognitive impairment and hippocampal neuroinflammation in rats with type 2 diabetes and sporadic Alzheimer-like disease. Behav Brain Res 2020; 379. doi: 10.1016/j.bbr.2019.112359.

[112] Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med 2018; 10(4). doi: 10.15252/emmm.201708689.

[113] Padhy DS, Vesmaker K, Banerjee S. Neuroprotective potential of tranilast in streptozotocin-induced sporadic Alzheimer's disease model targeting TXNIP-NLRP3 inflammasome pathway. Int Immunopharmacol 2025; 156. doi: 10.1016/j.intimp.2025.114691.

[114] Jia H, Qi X, Fu L, Wu H, Shang J, Qu M, et al. NLRP3 inflammasome inhibitor ameliorates ischemic stroke by reprogramming the phenotype of microglia/macrophage in a murine model of distal middle cerebral artery occlusion. Neuropathology 2022; 42(3): 181-189. doi: 10.1111/neup.12802.

[115] Hong Y, Liu Y, Yu D, Wang M, Hou Y. The neuroprotection of progesterone against Aβ-induced NLRP3-Caspase-1 inflammasome activation via enhancing autophagy in astrocytes. Int Immunopharmacol 2019; 74. doi: 10.1016/j.intimp.2019.05.054.

[116] Espinosa-Garcia C, Atif F, Yousuf S, Sayeed I, Neigh GN, Stein DG. Progesterone attenuates stress-induced NLRP3 inflammasome activation and enhances autophagy following ischemic brain injury. Int J Mol Sci 2020; 21(11). doi: 10.3390/ijms21113740.

[117] Meanti R, Criscione ML, Sartori E, Rizzi L, Bresciani E, Mauri M, et al. Anti-inflammatory effects of progesterone on human microglia via TLR4/NLRP3 pathway modulation: Relevance to drug-resistant epilepsy. Pharmaceuticals (Basel) 2026; 19(6). doi: 10.3390/ph19060920.

[118] Niu C, Zhang R, Zhang C, Liu C, Wu Z. Progesterone attenuates depression-like behaviors in chronic unpredictable stress via suppression of neuroinflammation. Behav Brain Res 2026; 497. doi: 10.1016/j.bbr.2025.115879.

[119] Nouri A, Hashemzadeh F, Soltani A, Saghaei E, Amini-Khoei H. Progesterone exerts antidepressant-like effect in a mouse model of maternal separation stress through mitigation of neuroinflammatory response and oxidative stress. Pharm Biol 2020; 58(1): 64-71. doi: 10.1080/13880209.2019.1702704.

[120] Aryanpour R, Pasbakhsh P, Zibara K, Namjoo Z, Beigi Boroujeni F, et al. Progesterone therapy induces an M1 to M2 switch in microglia phenotype and suppresses NLRP3 inflammasome in a cuprizone-induced demyelination mouse model. Int Immunopharmacol 2017; 51: 131-139. doi: 10.1016/j.intimp.2017.08.007.